Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset - PubMed (original) (raw)
. 2017 Jun 15;215(12):1807-1815.
doi: 10.1093/infdis/jix209.
Linlin Bao 2, Cong Chen 1, Tingting Zou 3, Ying Xue 1, Fengdi Li 2, Qi Lv 2, Songzhi Gu 2, Xiaopan Gao 1, Sheng Cui 1, Jianmin Wang 1, Chuan Qin 2, Qi Jin 1 4
Affiliations
- PMID: 28472421
- PMCID: PMC7107363
- DOI: 10.1093/infdis/jix209
Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset
Zhe Chen et al. J Infect Dis. 2017.
Abstract
Middle East respiratory syndrome coronavirus (MERS-CoV) infection in humans is highly lethal, with a fatality rate of 35%. New prophylactic and therapeutic strategies to combat human infections are urgently needed. We isolated a fully human neutralizing antibody, MCA1, from a human survivor. The antibody recognizes the receptor-binding domain of MERS-CoV S glycoprotein and interferes with the interaction between viral S and the human cellular receptor human dipeptidyl peptidase 4 (DPP4). To our knowledge, this study is the first to report a human neutralizing monoclonal antibody that completely inhibits MERS-CoV replication in common marmosets. Monotherapy with MCA1 represents a potential alternative treatment for human infections with MERS-CoV worthy of evaluation in clinical settings.
Keywords: MERS-CoV; common marmoset; human monoclonal antibody.
© Crown copyright 2017.
Figures
Figure 1.
MCA1 neutralized Middle East respiratory syndrome coronavirus (MERS-CoV) in vitro. The neutralizing activities of MCA1 against MERS-CoV were examined using Vero E6 cells. An irrelevant human immunoglobulin G (IgG) was used as a control.
Figure 2.
Prophylactic efficacy of MCA1 in common marmosets, which were intravenously inoculated with the antibody at doses of 5 mg/kg (designated G1) and 20 mg/kg (G2) and then challenged with Middle East respiratory syndrome coronavirus (MERS-CoV) 24 hours later. A control group was simultaneously infected and set up as a model (M) group. All groups were monitored twice daily for 3 days. A, Clinical scores (n = 3 per group). B, Temperature changes (n = 3 per group). C, Mean body weight changes (n = 3 per group). Results are presented as means with standard deviations. *P < .05 (t test).
Figure 3.
Therapeutic treatment using MCA1 in common marmosets, which were initially intratracheally infected with Middle East respiratory syndrome coronavirus (MERS-CoV), followed by intravenous inoculation with MCA1 at 2 (G3) or 12 (G4) hours, at 20 mg/kg. A control group was simultaneously infected and set up as a model (M) group. A, Clinical scores (n = 3 per group). B, Temperature changes (n = 3 per group). C, Mean body weight changes (n = 3 per group). Results are presented as means with standard deviations. *P < .05; †P < .01 (t test).
Figure 4.
Histopathology and viral titer detection. The common marmosets, were intravenously inoculated with MCA1 at doses of 5 mg/kg (G1) and 20 mg/kg (G2) and then challenged with Middle East respiratory syndrome coronavirus (MERS-CoV) 24 hours later, or were initially intratracheally infected with MERS-CoV, followed by intravenous inoculation with MCA1 at 2 (G3) or 12 (G4) hours, at 20 mg/kg. A control group was simultaneously infected and set up as a model (M) group. A, Histopathological appearance of pulmonary tissue from MERS-CoV–infected marmosets. Lungs of marmosets in the model group (M) showed acute bronchointerstitial pneumonia; the pulmonary alveoli were infiltrated by a large amount of inflammatory cells (arrowhead), with fibrin exudation (asterisk). The alveolar interstitium were thickened and pulmonary alveoli were filtrated by inflammatory cells (arrows) in the G1, G2, G3, and G4 groups. Scale bar, 100 μm. B, Viral titers from lung and trachea were determined 3 days after infection.
Figure 5.
Crystal structures of MCA1 fragment of antigen binding (Fab) in complex with Middle East respiratory syndrome coronavirus (MERS-CoV) receptor-binding domain (RBD). A, Crystal structure of MCA1/MERS-CoV RBD complex in graphic representation. The receptor-binding site (RBS) and core subdomain of MERS-CoV RBD are colored light pink and magenta, respectively; the heavy chain is green, and the light chain cyan. The ethylene glycol between the heavy and light chains and the N-linked glycans in the RBD are represented as magentas sticks. B, Closer view of the interaction between MCA1 Fab and the RBS. The RBS is depicted in surface representation. Three complementarity-determining regions (CDRs) of the heavy and light chains are colored orange. C, Detailed interactions between MCA1 and the RBS. Key residues are shown as sticks. D, Superimposed structures of MERS-CoV RBD binding to MCA1 and dipeptidyl peptidase (DPP4). The heavy and light chains of MCA1 are depicted in surface representation, and DPP4 is shown in red.
Similar articles
- Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
Tai W, Wang Y, Fett CA, Zhao G, Li F, Perlman S, Jiang S, Zhou Y, Du L. Tai W, et al. J Virol. 2016 Dec 16;91(1):e01651-16. doi: 10.1128/JVI.01651-16. Print 2017 Jan 1. J Virol. 2016. PMID: 27795425 Free PMC article. - Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection.
Qiu H, Sun S, Xiao H, Feng J, Guo Y, Tai W, Wang Y, Du L, Zhao G, Zhou Y. Qiu H, et al. Antiviral Res. 2016 Aug;132:141-8. doi: 10.1016/j.antiviral.2016.06.003. Epub 2016 Jun 14. Antiviral Res. 2016. PMID: 27312105 Free PMC article. - An Acute Immune Response to Middle East Respiratory Syndrome Coronavirus Replication Contributes to Viral Pathogenicity.
Baseler LJ, Falzarano D, Scott DP, Rosenke R, Thomas T, Munster VJ, Feldmann H, de Wit E. Baseler LJ, et al. Am J Pathol. 2016 Mar;186(3):630-8. doi: 10.1016/j.ajpath.2015.10.025. Epub 2015 Dec 24. Am J Pathol. 2016. PMID: 26724387 Free PMC article. - Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection.
Han HJ, Liu JW, Yu H, Yu XJ. Han HJ, et al. Viruses. 2018 Nov 30;10(12):680. doi: 10.3390/v10120680. Viruses. 2018. PMID: 30513619 Free PMC article. Review. - Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections.
Ying T, Li H, Lu L, Dimitrov DS, Jiang S. Ying T, et al. Microbes Infect. 2015 Feb;17(2):142-8. doi: 10.1016/j.micinf.2014.11.008. Epub 2014 Nov 29. Microbes Infect. 2015. PMID: 25456101 Free PMC article. Review.
Cited by
- Characterization and immunogenicity assessment of MERS-CoV pre-fusion spike trimeric oligomers as vaccine immunogen.
Ahuja R, Vishwakarma P, Raj S, Kumar V, Khatri R, Lohiya B, Saxena S, Kaur G, Singh G, Asthana S, Ahmed S, Samal S. Ahuja R, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2351664. doi: 10.1080/21645515.2024.2351664. Epub 2024 May 17. Hum Vaccin Immunother. 2024. PMID: 38757508 Free PMC article. - Marmosets as models of infectious diseases.
Herron ICT, Laws TR, Nelson M. Herron ICT, et al. Front Cell Infect Microbiol. 2024 Feb 23;14:1340017. doi: 10.3389/fcimb.2024.1340017. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38465237 Free PMC article. Review. - A platform technology for generating subunit vaccines against diverse viral pathogens.
Young A, Isaacs A, Scott CAP, Modhiran N, McMillan CLD, Cheung STM, Barr J, Marsh G, Thakur N, Bailey D, Li KSM, Luk HKH, Kok KH, Lau SKP, Woo PCY, Furuyama W, Marzi A, Young PR, Chappell KJ, Watterson D. Young A, et al. Front Immunol. 2022 Aug 18;13:963023. doi: 10.3389/fimmu.2022.963023. eCollection 2022. Front Immunol. 2022. PMID: 36059532 Free PMC article. - Animal models for studying coronavirus infections and developing antiviral agents and vaccines.
Lin Q, Lu C, Hong Y, Li R, Chen J, Chen W, Chen J. Lin Q, et al. Antiviral Res. 2022 Jul;203:105345. doi: 10.1016/j.antiviral.2022.105345. Epub 2022 May 21. Antiviral Res. 2022. PMID: 35605699 Free PMC article. Review. - The structure of a novel antibody against the spike protein inhibits Middle East respiratory syndrome coronavirus infections.
Jang TH, Park WJ, Lee H, Woo HM, Lee SY, Kim KC, Kim SS, Hong E, Song J, Lee JY. Jang TH, et al. Sci Rep. 2022 Jan 24;12(1):1260. doi: 10.1038/s41598-022-05318-4. Sci Rep. 2022. PMID: 35075213 Free PMC article.
References
- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814–20. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous